Proteocyte AI

Proteocyte AI A Canadian molecular diagnostics company with a novel technology that determines the risk of a head

Better cancer diagnostics

Our novel diagnostic technology, Straticyte™, determines the risk of a head and neck lesion becoming cancerous in the near future. If the risk is high, clinicians can provide early interventions. Clinicians can follow-up effectively with moderate and low risk lesions. Accurate early diagnosis and treatment will drastically improve the clinical outcomes and quality of life for people with head and neck cancer.

AI is transforming the world of dentistry!From personalized education for dental students to streamlined practice manage...
01/16/2025

AI is transforming the world of dentistry!

From personalized education for dental students to streamlined practice management and enhanced diagnostic capabilities, tools like ChatGPT and advanced algorithm AI tools such as the Straticyte advanced prognostic lab test are reshaping how dentistry is taught and practiced.

Key Innovations:
• Education: Interactive, AI-driven tools are helping students learn complex procedures and identify issues in radiographs.
• Practice Management: AI chatbots automate scheduling, patient communication, and even streamline insurance processes.
• Diagnosis: AI-powered scans and radiographs ensure early detection of dental issues and support treatment planning with unparalleled accuracy.

Advancements Beyond Dentistry: Edward J. Zuckerberg, DDS, FAGD, works with several companies involved in AI. He notes that Proteocyte AI, where he serves as a senior advisor, has developed an AI tool, Straticyte, capable of calculating “a score, expressed as a percentage likelihood that a particular lesion will undergo a malignant transformation over the next five years, giving both the surgeon and the patient a realistic basis for a treatment choice.”

https://www.agd.org/about-agd/publications-news/agd-impact

To address some challenges, dentists and policymakers are working to develop ethical standards, ensuring AI remains an adjunct to care rather than a replacement for human expertise.
https://proteocyte.com/straticyte/

Happy Holidays from the Proteocyte AI team!As we wrap up the year, we’re filled with gratitude for the trust and support...
12/24/2024

Happy Holidays from the Proteocyte AI team!

As we wrap up the year, we’re filled with gratitude for the trust and support of the oral health community. Together, we're advancing oral cancer care and making a meaningful impact on patients' lives.Proteocyte AI reflects on a few of their many milestone achievements in 2024 including establishing a footprint in the US market further commercializing the Straticyte advanced prognostic lab test in North America as well our 1st global market distribution agreements initiating expansion outside of North America. Proteocyte is also proud of being recognized by MedHealth Outlook as a Top 10 AI In Healthcare Solutions Provider 2024. https://proteocyte.com/proteocyte-ai-named-a-top-10-ai-healthcare-solution-providers-of-2024/

This holiday season, we’re reminded of the power of innovation and compassion in shaping a healthier future. Here's to a new year of breakthroughs, better outcomes, and brighter smiles!

We look forward to an exciting New Year as we continue to deliver personalized, high-accuracy solutions, like Straticyte (www.straticyte.com), to redefine oral cancer care.

– The Proteocyte AI team
www.proteocyte.com

Proteocyte Diagnostics Goes Global: Introducing Straticyte™ in Turkey!We’re thrilled to announce our partnership with Ph...
12/09/2024

Proteocyte Diagnostics Goes Global: Introducing Straticyte™ in Turkey!

We’re thrilled to announce our partnership with Pharmackt to bring Straticyte™, our pioneering Oral Cancer Stratification Test, to Turkey.
According to WHO's Global Cancer Observatory, Turkey faces a significant burden of oral cancer cases, with limited research and resources available. The tongue remains the most affected area, highlighting the urgent need for advanced diagnostic tools like Straticyte™.

Why Straticyte™ Matters:

Straticyte™ uses biomarker analysis to provide unique insights into oral lesions, empowering patients and doctors with earlier and more accurate prognoses. With early prediction we can help reduce the devastating impact of oral cancer and improve patient outcomes.
This marks a major step in Proteocyte's global expansion journey. As our CEO, Mark Hammar, puts it:
"Turkey is just the beginning. We’re committed to expanding access to Straticyte™ worldwide and helping markets in need of innovative solutions."

Read the full press release here: https://proteocyte.com/proteocyte-expands-globally-with-distribution-agreement-in-turkey/

Big News for Oral Health! Proteocyte is thrilled to announce that United Healthcare (UHC) will now be covering the Strat...
11/04/2024

Big News for Oral Health!
Proteocyte is thrilled to announce that United Healthcare (UHC) will now be covering the Straticyte™ test, an innovative diagnostic tool used to predict the risk of oral cancer. This is a major win for patients with oral precancer and for clinicians managing their care.

With UHC’s support, commercially-insured, Medicare Advantage, and Managed Medicaid patients will gain access to the Straticyte™ test across the United States. This breakthrough could transform care for individuals with oral precancer lesions by helping healthcare providers to identify potential malignancies early—without additional biopsies!

Mark Hammar, Proteocyte’s CEO, says, “This coverage will mean so much for patients and healthcare providers alike. It’s a step forward in fighting oral cancer, improving survival rates, and providing peace of mind.”

With over 50,000 diagnoses of oral cancer annually in North America, and a 65% 5-year survival rate due to late-stage detection, Straticyte is changing the paradigm of oral precancer (OPMD) care. Dr. Anthony Morlandt, Chief Medical Officer-USA, Head and Neck Surgeon / Oral Oncology, University of Alabama, Birmingham adds, “Straticyte, with this reimbursement, is an absolute game changer.”

Read full press release by visiting the following link: https://proteocyte.com/united-healthcare-now-reimbursing-straticyte-test/

Emerging research highlights the critical role of the S100A7 biomarker in the transformation to oral cancer. S100A7 has ...
10/28/2024

Emerging research highlights the critical role of the S100A7 biomarker in the transformation to oral cancer. S100A7 has been shown to promote cancer cell growth, migration, and invasion, as demonstrated by Dey et al. in their study published in Cancer Gene Therapy (2016).

Notably, out of 811 potential bioproteins, S100A7 emerged as the top performer in patients with Oral Potentially Malignant Disorders (OPMD). Ralhan et al. Mol Cell Proteomics (2008)

The Straticyte test from Proteocyte AI incorporates S100A7 and other cytomorphometric features, provides a personalized risk assessment for oral precancer patients

Elevated levels of S100A7 indicate a significantly increased risk of cancer development, regardless of dysplasia grading. This was corroborated by Kaur et al. in International Journal of Cancer (2013), emphasizing that OPMD lesions expressing S100A7—whether dysplastic or not—are more likely to progress to Squamous Cell Carcinoma (SCC).

The implications are profound: patients with high S100A7 expression face reduced oral cancer-free survival, averaging 68 months compared to 122 months for those with lower expression.
As we continue to delve into the potential of biomarkers like S100A7, we move closer to improving patient outcomes through early detection and personalized treatment strategies.

To learn more, visit our website: https://proteocyte.com/.

At Proteocyte AI, we harness the power of AI-driven digital technology to offer the Straticyte advanced prognostic lab t...
10/23/2024

At Proteocyte AI, we harness the power of AI-driven digital technology to offer the Straticyte advanced prognostic lab test, which calculates a personalized Risk Score (RS) for patients. This innovative approach not only provides valuable guidance but also offers peace of mind, as each patient’s RS is benchmarked against a large cohort with known clinical outcomes over a minimum of five years.

Why Choose STRATICYTE?
• Accurate & Objective: Our test analyzes the patient’s original biopsy tissue to deliver a personalized Risk Score, predicting the future behavior of precancerous oral lesions.
• Simple Integration: Just order the test, and Proteocyte takes care of the rest!
• No Additional Biopsy Required: We maximize patient comfort by using existing biopsy tissue.
• 5-Year Risk Score: Sensitivity and negative predictive value of 97%, ensuring accurate and individualized assessments.

Visit our website to learn more about StraticyteTM and learn how the 5-year risk score can help improve care management plans for your oral pre cancer patients https://proteocyte.com/.

S100A7: A Key Biomarker for Oral Pre-CancerS100A7, a protein encoded by an oncogene, is a promising biomarker for predic...
10/18/2024

S100A7: A Key Biomarker for Oral Pre-Cancer

S100A7, a protein encoded by an oncogene, is a promising biomarker for predicting the transformation of precancerous oral lesions or oral potentially malignant disorders (OPMDs) to oral cancer. Elevated levels of S100A7 have been correlated with malignant transformation in oral leukoplakia and erythroplakia, regardless of traditional histopathological grading.

Early research looked at 811 potential bioproteins and S100A7 performed the best.
Ralhan et al. Mol Cell Proteomics (2008)

The Straticyte test, which incorporates analysis of levels of S100A7 and other cytomorphometric features, provides a personalized risk assessment for oral precancer patients. This supports effective disease management, targeted treatment and improved outcomes. As research continues to advance, S100A7 shows to be a valuable tool for understanding and managing oral pre-cancerous lesions.

Learn more at: https://proteocyte.com/

Proteocyte AI is pleased to be an exhibit sponsor at AAOMS 2024, Sept. 12th to 14th in Orlando, FL.Visit the Proteocyte ...
09/09/2024

Proteocyte AI is pleased to be an exhibit sponsor at AAOMS 2024, Sept. 12th to 14th in Orlando, FL.
Visit the Proteocyte team at booth 1419 (across from AAOMS Member Pavilion store) to learn about the revolutionary STRATICYTE™ advanced prognostic lab test predicting risk of oral cancer. Watch this short video to learn more https://vimeo.com/926292958/26ef8c0d0c?share=copy

“Straticyte’s real value is its ability to accurately & objectively identify and stratify elevated versus low-risk patients, guide OPMD patient management decisions and encourage better patient follow up compliance. Straticyte should reduce the number of patients presenting with advanced disease, thereby increasing 5-year survival rates, lowering direct and indirect health care costs and diminishing Oral Cancer morbidity.” - James C. Melville, DDS FACS Professor, Department of Oral & Maxillofacial Surgery Oral, Head & Neck Oncology and Microvascular Reconstructive Surgery University of Texas Health Science Center at Houston

Visit https://proteocyte.com/

Take Charge of Your Health“Using STRATICYTE™ both the clinician and the patient should have peace of mind that their ora...
08/26/2024

Take Charge of Your Health

“Using STRATICYTE™ both the clinician and the patient should have peace of mind that their oral precancer, also known as Oral Potentially Malignant Disorder (OPMD), diagnosis is being managed with the most advanced technology currently available.“
- Barrie Renick, BSc, DDS, Dip Oral Path, Dip Oral Surgery, MRDC(C)

Proteocyte AI’s STRATICYTE™ test enhances standard histopathology results by providing your healthcare professional with a personalized risk score for your oral lesion. This score indicates whether your lesion is low risk or at an elevated risk of developing into cancer within the next five years. By combining this objective risk score with histopathology results, healthcare professionals can create a more effective treatment plan. No additional biopsy is needed! The physician just needs to order the test through the online portal, and Proteocyte takes care of the rest. It’s that simple!

Learn more about STRATICYTE™ by visiting https://proteocyte.com/straticyte/

STRATICYTE – Request the test, Proteocyte AI does the rest!Proteocyte AI’s STRATICYTE test offers accurate and objective...
08/19/2024

STRATICYTE – Request the test, Proteocyte AI does the rest!

Proteocyte AI’s STRATICYTE test offers accurate and objective prediction of oral cancer risk by providing a personalized risk score, which supports managing Oral Pre-cancer (OPMD) patients. Oral cancer can necessitate extensive surgery, significantly impact quality of life. Despite advancements in treatment, the 5-year overall survival rates for oral cancer have barely improved over recent decades, remaining at a concerning 50-65% in Western countries and below 20% in many other regions. In the US, someone dies from oral cancer every 45 minutes. Early prognosis and early management are critical because oral cancer, at late stages, is very difficult and costly to treat.

STRATICYTE is an extensively validated, tissue-based advanced prognostic test that applies AI-driven software to predict risk of developing oral cancer. Straticyte is easy to integrate into clinical practice. No additional biopsy is required as the patient’s original biopsy tissue is used for the test. Because every lesion is unique, Straticyte provides the treating physician and patient with additional information about the lesion – an individualized risk score. This additional information supports effective disease management and care.

Order the test: https://proteocyte.com/ordering-options/

Proteocyte AI is honoured to be among the Top 10 AI in Healthcare Solution Providers of 2024, alongside leaders advancin...
07/26/2024

Proteocyte AI is honoured to be among the Top 10 AI in Healthcare Solution Providers of 2024, alongside leaders advancing AI integration in healthcare. Our innovative STRATICYTE test employs AI to accurately predict oral cancer progression, empowering healthcare professionals with critical insights to support effective clinical management. Read Medhealth’s article about Proteocyte AI’s groundbreaking work: https://medhealthoutlook.com/proteocyte-ai/

“As a company, Proteocyte AI hopes to continue making a positive impact on the lives of patients at risk of oral cancer, as well as increasing its reach to clinicians and patients globally, reducing the mortality, morbidity, and the financial burden of oral cancer,” says Mark Hammar, CEO of Proteocyte AI.

“Due to the uncertain progression of pre-cancerous lesions, STRATICYTE provides a quantified tool for predicting the tra...
07/16/2024

“Due to the uncertain progression of pre-cancerous lesions, STRATICYTE provides a quantified tool for predicting the transformation of a lesion to a life-threatening cancer. All in all, STRATICYTE has been an invaluable tool in providing my patients with the best care possible. I am confident that STRATICYTE will be a powerful tool in the management of precancerous leukoplakia.” - Dr James C. Melville, DDS FACS

Proteocyte AI’s innovative STRATICYTE test is an extensively validated, tissue-based prognostic test that applies AI-driven software to accurately and objectively predict the progression of pre-malignant lesions to invasive oral cancer providing patients and physicians with an individualized 5-year risk score. It is a test that supports healthcare professionals with patient management plans to improve outcomes for patients at elevated risk for developing oral cancer, while reassuring those patients who have minimal to no risk of progression. Learn more about STRATICYTE by visiting https://proteocyte.com/straticyte/

STRATICYTE – Request the test, Proteocyte AI does the rest!Proteocyte AI’s STRATICYTE test accurately and objectively pr...
07/12/2024

STRATICYTE – Request the test, Proteocyte AI does the rest!

Proteocyte AI’s STRATICYTE test accurately and objectively predicts risk of oral cancer providinga personalized risk score to support management of oral potentially malignant disease patients. Oral cancer often requires major surgery, may severely impact your quality of life and even lead to death. While there have been significant advances in the treatment of Oral Cancer, the 5-year overall survival rates have shown little improvement over the past few decades, and rest
at an embarrassing overall rate of 50-65% in western societies, and less than 20% in many other regions. In the US, 1 life is claimed by Oral Cancer every 45 minutes. Early prognosis and early management are critical because oral cancer, at late stages, is very difficult and costly to treat.

STRATICYTE is an extensively validated, tissue-based prognostic test that applies AI-driven software to predict risk of developing oral cancer. Because every lesion is unique, Straticyte provides the treating physician and patient with additional information about the lesion – an individualized risk score. This additional information supports effective disease management and care.

Learn more about Proteocyte AI’s work at https://proteocyte.com/

“With STRATICYTE leading the way, Proteocyte AI is poised to make a profound impact on oral cancer management, providing...
06/25/2024

“With STRATICYTE leading the way, Proteocyte AI is poised to make a profound impact on oral cancer management, providing hope and healing to patients and healthcare professionals around the world.”

We are excited to announce that Proteocyte AI is one of the Top 10 AI Healthcare Solution Providers of 2024. This list includes innovative companies that are not only addressing the current needs of the healthcare system, but also paving the way for a future where AI-driven insights and innovations lead to superior health outcomes and a more sustainable healthcare system. To learn more, read: https://medhealthoutlook.com/proteocyte-ai/

Proteocyte AI is proud to be a part of the Top 10 AI in Healthcare Solution Providers of 2024. This list comprises of in...
06/17/2024

Proteocyte AI is proud to be a part of the Top 10 AI in Healthcare Solution Providers of 2024. This list comprises of innovative companies that are at the forefront of integrating AI into healthcare, creating solutions that are reshaping the industry, and leveraging cutting-edge AI technologies to make a significant difference in patient care and operational efficiency. Read Medhealth’s article about Proteocyte AI’s innovative work: https://medhealthoutlook.com/proteocyte-ai/

Proteocyte AI has invested over 12 years in research and development to create a proprietary prognostic software platform-based technology. This innovative platform digitally analyzes specific biomarkers, known as predictive proteomics, leveraging artificial intelligence to predict an individual’s progression to cancer accurately and objectively. By harnessing the power of AI, Proteocyte AI has revolutionized cancer prognosis, providing healthcare professionals with invaluable insights to guide patient care. To learn more, visit https://proteocyte.com/

Proteocyte AI will be at the 68th annual CAOMS conference in Saskatoon on June 17. Come visit us at booth  #4 and learn ...
06/14/2024

Proteocyte AI will be at the 68th annual CAOMS conference in Saskatoon on June 17. Come visit us at booth #4 and learn more about our innovative Straticyte™ test.

Straticyte™ is a test that leverages the power of AI technology to predict the progression of pre-malignant lesions to invasive oral cancer. It enables healthcare professionals to customize patient management plans to improve outcomes for patients at elevated risk for developing oral cancer, while reassuring those patients who have minimal to no risk of progression.

Straticyte™is the only predictor that can objectively distinguish oral lesions at elevated risk of becoming cancerous from those with little to no risk.

Learn more about our innovative Straticyte advanced prognostic lab test by visiting www.proteocyte.com

Proteocyte AI is pleased to announce the appointment of Dr. Joseph Geraci, Ph.D. to the new role of Strategic Advisor, A...
06/13/2024

Proteocyte AI is pleased to announce the appointment of Dr. Joseph Geraci, Ph.D. to the new role of Strategic Advisor, AI.

Dr. Geraci has a very strong academic and research background which includes a Master of Science in Mathematics from the University of Toronto, a Doctor of Philosophy (Mathematical Physics/Applied Mathematics) from the University of Toronto and the University of Southern California as well several research initiatives, clinical publications and three post-doctoral awards.

Mark Hammar, CEO of Proteocyte expressed, “We are very excited to have Joe joining us here at Proteocyte. Joe’s vast knowledge in the AI space is a key addition to our team as we look to bring our AI capabilities fully in-house allowing us to broaden the use of AI not only for our current assay but to develop additional capabilities.”

Learn more about Proteocyte AI’s innovative work by visiting https://proteocyte.com/

Proteocyte AI is pleased to announce the appointment of Mark Rood as their Director of Key Accounts, US.  Mr. Rood bring...
06/13/2024

Proteocyte AI is pleased to announce the appointment of Mark Rood as their Director of Key Accounts, US.

Mr. Rood brings over 15 years of experience in the U.S. surgical device industry including the dental surgery market with companies like Henry Schein, NuVasive and most recently Axogen Inc., successfully contributing to high growth and adoption of their allograft nerve in the U.S. market. He has a proven track record of success in market development, executing commercialization plans as well as facilitating clinical education programs for surgeons across the U.S. .

Proteocyte’s CEO Mark Hammar said of the announcement, "The addition of Mark Rood to our U.S. team is a critical next step in our commercialization plan for the U.S. market. Mark brings a tremendous amount of experience in the Oral Health space along with several well-established positive relationships with Key Oral Surgeons across the U.S."

Learn more about Proteocyte AI’s innovative work by visiting https://proteocyte.com/

Address

Toronto, ON
M5G1L7

Alerts

Be the first to know and let us send you an email when Proteocyte AI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Proteocyte AI:

Share